IClick Interactive Asia Gets Preliminary Non-binding Proposal At $6.75/ADS In Cash

iClick Interactive Asia Group Limited (ICLK) said that it has received a preliminary non-binding indicative proposal dated September 23, 2021 from PAG Pegasus Fund LP and/or its designated affiliates, entities and co-investors and Oasis Management Company Ltd and/or its designated affiliates, entities and co-investors collectivelly called as "Proposing Buyers" to acquire all of the outstanding shares of the Company for US$6.75 per ADS in cash.

iClick Interactive Asia cautioned its shareholders that the Board has just received the Proposal Letter and has not had an opportunity to carefully review or evaluate the proposal, or make any decision with respect to the Company's response to the proposal.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT